Biotech's great run has been achieved despite a number of macroeconomic events along the way that periodically spooked the general markets, but left the confidence in the industry largely unscathed.
It wasn't the perfect second quarter, but we'll take it. U.S. investments in private companies tracked by BioWorld in the first quarter of the year started off like gangbusters, more than doubling the funding in the year-ago quarter.
HONG KONG – Before they travel to Mecca every year for the Hajj, an annual pilgrimage, million of Muslims have to be vaccinated. Saudi Arabia's Ministry of Health requires that all visitors older than 2 produce a certificate of vaccination that shows they have been vaccinated against meningitis. more »
In a deal that both partners cited as "transformative" for their companies and for the field of immunotherapeutics, Celgene Corp. enlisted Juno Therapeutics Inc. as a partner in a broad, global collaboration to leverage T-cell therapies and develop treatments targeting cancer and autoimmune diseases. more »
- Vertex widens CF net: FDA approves Orkambi for largest patient subset
- Vectors mature: Biogen inks potential $1B AGTC gene therapy eye deal
- Janssen's Sylvant wins approval in Brazil for rare disease MCD
- Biotech slips on Greece debt crisis and market turbulence
- Gene therapy to treat cystic fibrosis proves eff...
Biotech's great run has been achieved despite a number of macroeconomic events along the way that periodically spooked the general markets, but left the confidence in the industry largely unscathed. Although the sector has managed to shrug off those stock market perturbations, it was a different story at the end of second quarter as the markets headed south.
Scientists made progress toward the goal of mammalian tissue regeneration with the publication of studies showing that mice could be induced to self-repair ear wounds by a drug treatment that increased levels of the transcription factor HIF-1alpha.
"We could convert an animal into a healer," senior author Ellen Heber-Katz, of the Lankenau Institute for Medical Research, told BioWorld Today.READ MORE »
- Study suggests ways to help PI3k inhibitors live up to their potential »
- Inhibitor discovery offers promising new anticoagulant »
- Human genetics no cure-all, but good medicine for drug development »
- Mushroom minimizes mouse models of obesity »
- Amylase gene delinked from body mass index »
- Altering mRNA sequence, not bases, can deliver therapeutic protein »
- Molecular modeling yields potential new Alzheimer's treatments »
- New findings show path for mucosal vaccines »
- Immune system defense is NET loss in wound healing »
- Utopia, dystopia: Separating truth from fiction in bioethics discussionsJune 03, 2015 | 12:05 AM | Posted by: Jennifer Boggs
- A world of intrigue, from Missoula to Mars: BioWorld’s 9th Annual Summer Reading ListMay 26, 2015 | 6:31 PM | Posted by: Marie Powers
- You’ve come a long way, baby, but still a long way to goMay 04, 2015 | 2:44 PM | Posted by: Mari Serebrov
- As researchers unlock the brain’s mysteries, let’s not overlook the real questionsApril 27, 2015 | 4:35 PM | Posted by: Marie Powers
- Talk to your doctor: How even annoying DTC ads can contribute to patient communication April 15, 2015 | 4:48 PM | Posted by: Jennifer Boggs
Partners in Focus
Cast Your Vote
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter